Impact of XXXX on platelet function and fibrinolysis.

@entity1 @entity64 @entity556 @entity66 @entity63 @entity1423 @entity3926 @entity14534 @entity955
BACKGROUND: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of @entity14534 (DE) due to decreased @entity556 levels in @entity1 with @entity64 or transient @entity63 attack and @entity955 ( @entity955 ). METHODS: Consecutive @entity1 with @entity66 and @entity955 that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous @entity556 potential (ETP) and hemoclot @entity556 inhibitors (HTI), were also performed in order to detect any possible correlation between @entity3926 plasma levels, its anticoagulant activity and the intensity of @entity1423 or fibrinolysis. RESULTS: A total of nineteen @entity1 fulfilled our inclusion criteria (mean age 62.3  7.2years; 47% males; median CHADS2-score: 3; interquartile range: 2-4). DE treatment was associated with a significant reduction of the lysis index (LI60) at 60min (p=0.036), and prolongation of the PFA-100 CEPI closure time (p=0.024). After @entity3926 treatment, abnormal PFA-100 results were obtained in two @entity1 (11%, 95% CI: 2%-33%). DE levels (determined by HTI) were strongly inversely correlated (rho=-0.85; p<0.001) with the area under the curve (AUC) values in ETP assay.   o association was found between HTI and PFA-100 CEPI CT (p=0.64), or LI60 measurements (p=0.60). CONCLUSIONS: Our findings indicate that DE might affect platelet function and fibrinolysis and highlight the potential role of ETP as an alternative option in DE monitoring. The intensity and clinical relevance of DE antiplatelet and fibrinolytic effects require further investigation.
